Aclaris Therapeutics

Historical price data

Aclaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies for immuno-inflammatory diseases with high unmet need. The company's core strength is its proprietary KINect® platform, which enables rapid discovery of selective kinase inhibitors. Having divested its commercial assets, Aclaris now focuses entirely on advancing a promising pipeline, including candidates for rheumatoid arthritis, alopecia areata, and atopic dermatitis, aiming to address critical 'white spaces' in treatment paradigms.

The proprietary KINect® platform is an integrated drug discovery system that uses structure-based design and a focused chemical library to rapidly develop selective small molecule kinase inhibitors, often targeting unique cysteine residues for covalent binding.

Aclaris competes in a crowded field dominated by large pharma companies with extensive portfolios of biologics and JAK inhibitors. Its differentiation hinges on its novel kinase targets (MK2, ITK) and its efficient KINect® platform, but it must demonstrate clear clinical advantages to capture market share.